Comparison · NCT00306202-4f1fc595
Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) vs Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2): Number of Participants With Major Molecular Response (MMR) in Stratum 2/3 (Ph+ ALL or AP/BP-CML)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) vs Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2): Number of Participants With Major Molecular Response (MMR) in Stratum 2/3 (Ph+ ALL or AP/BP-CML). Trial comparisons, record NCT00306202-4f1fc595. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00306202-4f1fc595
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.25 | 0.0715 | 0.591 | wilson | |
| Risk in group 2 | 0.667 | 0.354 | 0.879 | wilson | |
| Risk difference, group 1 minus group 2 | -0.417 | -0.694 | 0.0456 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.375 | 0.104 | 1.36 | log | |
| Odds ratio, group 1 over group 2 | 0.167 | 0.0201 | 1.38 | log | |
| Number needed to treat, for one fewer participant with the outcome on Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) than on Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) | 2.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) | Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML). Dasatinib 60 mg/m\^2 QD, as long as clinical benefit was maintained. | 2 | 8 | OG000 |
| Group 2 | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) | Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML). Dasatinib 80 mg/m\^2 QD, as long as clinical benefit was maintained. | 6 | 9 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Major Molecular Response (MMR) in Stratum 2/3 (Ph+ ALL or AP/BP-CML)
- Description
Molecular response was calculated by measuring BCR-ABL transcripts in blood during treatment using qPCR assay. MMR: Ratio of the BCR-ABL to ABL \<10\^-3 or a ≥3 log reduction from baseline in participants with p190 variant; ratio of the BCR-ABL to ABL \<10\^-3 on the international scale in participants with p210 variant. BCR-ABL=the fused gene found in participants with this type of CML.
- Time frame
- At baseline (within 3 weeks before initiation of study therapy), After hematologic response, EOT (Median duration of therapy in months: Stratum 2/3=3.02 [Range: 0.53-37.72])
- Population
- All treated participants (14 with p190 variant and 3 with p210 variant BCR-ABL transcripts) in stratum 2/3: Participants who received at least 1 dose of study therapy.
Source ClinicalTrials.gov
Trial
- Title
- Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia
- NCT number
- NCT00306202
- Phases
- PHASE1
- Conditions
- Leukemia
- Interventions
- Dasatinib, Dasatinib, Dasatinib
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2012-07-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00306202?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00306202-4f1fc595